Ø Hjertner

Summary

Affiliation: Norwegian University of Science and Technology
Country: Norway

Publications

  1. ncbi request reprint Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease
    O Hjertner
    Institute of Cancer Research and Molecular Biology, Norwegian University of Science and Technology, Trondheim, Norway
    Blood 94:3883-8. 1999
  2. ncbi request reprint Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells
    O Hjertner
    The Institute of Cancer Research and Molecular Biology, Norwegian University of Science and Technology, Trondheim, Norway
    Br J Haematol 109:815-22. 2000
  3. ncbi request reprint Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells
    O Hjertner
    Institute of Cancer Research and Molecular Biology, and the Section of Hematology, Institute of Environmental Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Blood 97:516-22. 2001
  4. ncbi request reprint Identification of new targets for therapy of osteolytic bone disease in multiple myeloma
    Ø Hjertner
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Curr Drug Targets 6:701-11. 2005
  5. ncbi request reprint Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins
    M Børset
    Arkansas Cancer Research Center and Departments of Pathology and Anatomy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Blood 96:2528-36. 2000
  6. ncbi request reprint High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity
    C Seidel
    Institute of Cancer Research and Molecular Biology, Norwegian University of Science and Technology, Trondheim, Norway
    Blood 96:3139-46. 2000

Collaborators

Detail Information

Publications6

  1. ncbi request reprint Hepatocyte growth factor (HGF) induces interleukin-11 secretion from osteoblasts: a possible role for HGF in myeloma-associated osteolytic bone disease
    O Hjertner
    Institute of Cancer Research and Molecular Biology, Norwegian University of Science and Technology, Trondheim, Norway
    Blood 94:3883-8. 1999
    ..Thus, myeloma-derived HGF can influence the bone marrow environment both as a soluble and a surface-bound factor. Furthermore, HGF emerges as a possible factor involved in myeloma bone disease by its ability to induce IL-11...
  2. ncbi request reprint Expression of urokinase plasminogen activator and the urokinase plasminogen activator receptor in myeloma cells
    O Hjertner
    The Institute of Cancer Research and Molecular Biology, Norwegian University of Science and Technology, Trondheim, Norway
    Br J Haematol 109:815-22. 2000
    ..We conclude that myeloma cells are able to produce uPA and uPAR. This opens up a possible role of the uPA system in myeloma cell invasion and in the proteolytic digestion of bone matrix...
  3. ncbi request reprint Bone morphogenetic protein-4 inhibits proliferation and induces apoptosis of multiple myeloma cells
    O Hjertner
    Institute of Cancer Research and Molecular Biology, and the Section of Hematology, Institute of Environmental Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Blood 97:516-22. 2001
    ..BMP-4 or analogues may be attractive therapeutic agents in MM because of possible beneficial effects on both tumor burden and bone disease...
  4. ncbi request reprint Identification of new targets for therapy of osteolytic bone disease in multiple myeloma
    Ø Hjertner
    Department of Cancer Research and Molecular Medicine, Norwegian University of Science and Technology, Trondheim, Norway
    Curr Drug Targets 6:701-11. 2005
    ..The aim of this review is to focus on the principles of bone biology for a better understanding of the development of myeloma bone disease and to identify possible therapeutic targets...
  5. ncbi request reprint Syndecan-1 is targeted to the uropods of polarized myeloma cells where it promotes adhesion and sequesters heparin-binding proteins
    M Børset
    Arkansas Cancer Research Center and Departments of Pathology and Anatomy, University of Arkansas for Medical Sciences, Little Rock, AR, USA
    Blood 96:2528-36. 2000
    ..These data indicate that syndecan-1 is targeted to the uropod of polarized myeloma cells and that this targeting plays a role in promoting cell-cell adhesion and may also regulate the biological activity of heparin-binding cytokines...
  6. ncbi request reprint High levels of soluble syndecan-1 in myeloma-derived bone marrow: modulation of hepatocyte growth factor activity
    C Seidel
    Institute of Cancer Research and Molecular Biology, Norwegian University of Science and Technology, Trondheim, Norway
    Blood 96:3139-46. 2000
    ..HGF is only one of several heparin-binding cytokines associated with myeloma. These data indicate that soluble syndecan-1 may participate in the pathology of myeloma by modulating cytokine activity within the bone marrow...